[
  {
    "ts": null,
    "headline": "Eli Lilly and Co (LLY): Expands Genetic Hearing Loss Pipeline with $1.3B RNA Therapy Partnership",
    "summary": "On May 16, Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural hearing loss, with milestone payments exceeding $1.3 billion. Rznomics will lead early-stage research, while Lilly handles clinical development and commercialization using RNA editing, a reversible alternative to CRISPR. The collaboration complements Lilly’s existing genetic hearing […]",
    "url": "https://finnhub.io/api/news?id=1af273f3e75ca96a4175d62181131c575faff4aa07f5746173371dfe8482a31d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747517286,
      "headline": "Eli Lilly and Co (LLY): Expands Genetic Hearing Loss Pipeline with $1.3B RNA Therapy Partnership",
      "id": 134567758,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "On May 16, Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural hearing loss, with milestone payments exceeding $1.3 billion. Rznomics will lead early-stage research, while Lilly handles clinical development and commercialization using RNA editing, a reversible alternative to CRISPR. The collaboration complements Lilly’s existing genetic hearing […]",
      "url": "https://finnhub.io/api/news?id=1af273f3e75ca96a4175d62181131c575faff4aa07f5746173371dfe8482a31d"
    }
  },
  {
    "ts": null,
    "headline": "Trump administration not backing down on Big Pharma pressure campaign",
    "summary": "The pharmaceutical industry's patience is wearing thin with the Trump administration's pressure. But the administration doesn't care.",
    "url": "https://finnhub.io/api/news?id=76fcd69c6045725b019f23ad0b4cec795c0cd81ef0f8a8bb1e378c46cad73ebf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747488631,
      "headline": "Trump administration not backing down on Big Pharma pressure campaign",
      "id": 134567759,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The pharmaceutical industry's patience is wearing thin with the Trump administration's pressure. But the administration doesn't care.",
      "url": "https://finnhub.io/api/news?id=76fcd69c6045725b019f23ad0b4cec795c0cd81ef0f8a8bb1e378c46cad73ebf"
    }
  },
  {
    "ts": null,
    "headline": "Why UnitedHealth Is Down 50% In A Month And What Happens Next",
    "summary": "UnitedHealth Group faces real PBM reform risks, but legal paths, financials, and market pricing suggest opportunity in uncertainty. Read why UNH stock is a buy.",
    "url": "https://finnhub.io/api/news?id=0a2c49f88494a4e96ee6dc723b8ca87eeb7cc238c8ba4007a1bee750e48565ef",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747466148,
      "headline": "Why UnitedHealth Is Down 50% In A Month And What Happens Next",
      "id": 134539180,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2214714811/image_2214714811.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "UnitedHealth Group faces real PBM reform risks, but legal paths, financials, and market pricing suggest opportunity in uncertainty. Read why UNH stock is a buy.",
      "url": "https://finnhub.io/api/news?id=0a2c49f88494a4e96ee6dc723b8ca87eeb7cc238c8ba4007a1bee750e48565ef"
    }
  }
]